Their focus shifted to crafting specialized antibodies, widely known as monoclonal antibodies, capable of disrupting the PD-1/PD-L1 interaction to counteract T-lymphocytes' suppression and bolster the immune response against cancer cells [27]. Antibodies aimed at PD-1 or its counterpart, PD-L1, breathe new life into the T-cells in a dysfunctional state, rekindling their ability to fend off cancer cells. This evidence concerns the gene PDCD1 and cancer.